Recent Research on Analytical Methods of Analysis of Artemether and Lumefantrine: a Review
New antimalarial tranquilize investigates are concentrating on promising focuses so as to grow new medication competitors. Essential digestion and biochemical procedure in the malarial parasite, for example Plasmodium falciparum can assume a vital job in the distinguishing proof of these objectives. In any case, the rise of protection from antimalarial drugs is a heightening far reaching issue with the advancement of antimalarial medicates improvement. The pharmaceutical enterprises are focused on new medication improvement because of the worldwide acknowledgment of this perilous protection from the right now accessible antimalarial treatment. The HPLC, UV and HPTLC techniques are accessible for the examination of Artemether and Lumefantrine the as of late utilized medication for malaria are surveyed in this article.
2) Muheet Saifi, Tanveer Beg, Halim Harrath, Saleh Al-QuraishyAntimalarial drugs: Mode of action and status of resistance. Afr. J. Pharmacy and Pharmacology. 2013; 7(5):148-156.
3) Sahil Kumar, T.R. Bhardwaj, D.N. Prasad, Rajesh K. Singh, et.al, Drug targets for resistant malaria: Historic to future perspectives. Biomedicine & Pharmacotherapy. 2018; 104: 8–27.
4) Y Bergqvist, F.C. Churchill, Detection and Determination of Antimalarial Drugs and Their Metabolites in Body Fluids. J Chromatogr. 1988; 434(1):1-20.
5) Monica Escola Casas, Martin Hansen , Kristine. A Krogh ,Bjarne Styrishave, et.al., Analytical sample preparation strategies for the determination of antimalarial drugs in human whole blood, plasma and urine. J. Chromatography B. 2014; 962; 109-131.
6) Kalpesh N. Patel, Jayvadan K. Patel, A Review - Qualitative and Quantitative Analysis of Antimalarial Drugs and their Metabolites in Body Fluids. J. Current Pharmaceutical Research. 2010; 2(1): 5-14.
7) Wikipedia. Artemether [Internet]. 2020 [cited 2020 Sept.13]. Available from:
8) Drugbank. Artemether [Internet]. 2020 [cited 2020 Sept.13]. Available from:
9) Drugbank. Lumefantrine [Internet]. 2020 [cited 2020 Sept.13]. Available from:
10) A. A. Amin, G. O. Kokwaro, Antimalarial drug quality in Africa. Journal of Clinical Pharmacy and Therapeutics. 2007; 32:429-440.
11) David Harvey, Modern Analytical Chemistry, The McGraw-Hill Companies, Ist edition; 2000.
12) Douglas Arvid Skoog, F. James Holler, Timothy Alan Nieman Principles of Instrumental Analysis, Congress Cataloging publication, 5th edition; 1980.
13) Lloyd R. Snyder, Joseph J. Kirkland, John W. Dolan, Introduction to Modern Liquid Chromatography, A John Wiley & Sons, Inc., Publication, 3rd edition; 2010.
14) Pratap Y. Pawar, Manisha P. Chavan, Geetanjali K. Ghanwat, Manish A. Raskar, et. al, Validated spectrophotometric method for quantitative determination of Artemether in pharmaceutical formulation. Der Pharma Chemica. 2011; 3(3):135-139.
15) M. Gabriels, J. A. Plaizier-Vercammen, Densitometric Thin-Layer Chromatographic Determination of Artemisinin and its Lipophilic Derivatives, Artemether and Arteether. Journal of Chromatographic Science. 2003; 41:359-366.
16) Lata P. Kothapalli*, Karan S. Vighne, Rabindra K. Nanda, Asha B. Thomas,Development and Validation of a Stability Indicating HPTLC Method for Estimation of Artemether in Bulk and Formulated dosage form. Asian Journal of Research in Chemistry. 2015; 8 (10):635-642.
17) Niting.G. Tayade, Mangal S Nagarsenker , Validated HPTLC method of analysis for artemether and its formulations. Journal of Pharmaceutical and Biomedical Analysis. 2007; 43:839-844.
18) Bantuzeka Chimanuka, M. Gabriels, M. R. Detaevernier, J. A. Plaizier-Vercammen, Preparation of β-artemether liposomes, their HPLC–UV evaluation and relevance for clearing recrudescent parasitaemia in Plasmodium chabaudi malaria-infected mice. Journal of Pharmaceutical and Biomedical Analysis. 2002; 28:13–22.
19) Alankar Shrivastava, R Issarani, Badri Prakash Nagori, Stability Indicating High-Performance Liquid Chromatography Method for the Estimation of Artemether in Capsule Dosage Forms. J Young Pharm. 2010; 2(1):79-84.
20) Deepti Jain, Pawan Kumar Basniwal, Forced Degradation Profiling of Artemether by Validated Stability- Indicating RP-HPLC-DAD Method. Hacettepe University. Journal of the Faculty of Pharmacy. 2013; 33(1):41-58.
21) Warunee Hanpithakpong, Benjamas Kamanikom, Pratap Singhasivanon, Nicholas J White, et al., A liquid chromatographic-tendam mass spectrometric method for determination of artemether and it’s metabolite dihydroartemisinin in human plasma. Bioanalysis. 2009; 1(1):37-46.
22) Liusheng Huang, Anura L Jayewardene, Xiaohua Li, Florence Marzan, et. al., Development and validation of a high-performance liquid chromatography/tandem mass spectrometry method for the determination of artemether and its active metabolite dihydroartemisinin in human plasma, J. Pharm. Biomed. Anal. 2009; 50:959–965.
23) Fazli Khuda, Zafar Iqbal, Yasar Shah, Muhammad Abbas, A High‑Resolution LC–MS/MS Method for the Quantitative Determination of Artemether and Its Metabolite Dihydroartemisinin in Human Plasma and Its Application to Pharmacokinetic Studies. Chromatographia. 2016; 79:655.
24) Kirsten Vandercruyssen, Matthias D. Hondt, Valentijin Vergote, Herwig Jansen, et. al., LC–UV/MS quality analytics of paediatric artemether formulations. Journal of Pharmaceutical Analysis. 2014; 4(1):37–52.
25) Vidya Navaratnam, S. M. Mansor, L. K. Chin, Mohd Nizam Mordi, et.al.,Determination of artemether and dihydroartemisinin in blood plasma by high performance liquid chromatography for application in clinical pharmacological studies. J. Chromatogr. B. 1995; 669:289–294.
26) C.G. Thomas, S. A.Ward, G. Edwards, Selective determination, in plasma, of artemether and major metabolite, dihydroartemisinin, by high performance liquid chromatography with ultraviolet detection. Journal of Chromatography. 1992; 583:131-136.
27) C. Souppart, et al., Development and validation of a high-performance liquid chromatography-mass spectrometry assay for the determination of artemether and its metabolite dihydroartemisinin in human plasma. J. Chromatogr. B 2002; 774:195-203.
28) Bin Shi, Yunqiu Yu, Zhondong Li, Li Zhang,et. al., Quantitative analysis of artemether and its metabolite dihydroartemisinin in human plasma by LC with tandem mass spectrometry. Chromatographia. 2006; 64:523–530.
29) Igor R S Magalhaes, Valquiria A P Jabor, Anizia Faria, Carol H. Collins, et. al., Determination of β-artemether and its main metabolite dihydroartemisinin in plasma employing liquid-phase microextraction prior to liquid chromatographic–tandem mass spectrometric analysis. Talanta 2010; 81:941-947.
30) Sumia. Mohamed, Sami Khalid, Stephen Andrew Ward, Terence see Ming Wan, et. al., Simultaneous determination of artemether and its major metabolite dihydroartemisinin in plasma by gas chromatography–mass spectrometry-selected ion monitoring. Journal of Chromatography B. 1999; 731:251–260.
31) S. Sharma, M.C.Sharma, Simultaneous UV Spectrophotometric Method for the Estimation of Lumefantrine in Pharmaceutical Dosage Forms. World Journal of Chemistry. 2011; 6 (2):75-79.
32) R. Arun, Anton Smith Atul Gnana Dhas, Development of Analytical Method for Lumefantrine by UV Spectrophotometry. Int. J. Res. Pharm. Sci. 2010; 1(3):321-324.
33) da Costa Cesar I, Nogueira FH, Pianetti GA, Comparison of HPLC, UV spectrophotometry and potentiometric titration methods for the determination of lumefantrine in pharmaceutical products. Journal of Pharmaceutical and Biomedical Analysis. 2008; 48:223–226.
34) A. Annerberg, T. Singtoroj, P. Tipmanee, N. White, et.al., High throughput assay for the determination of lumefantrine in plasma. J. Chromatogr. B. 2005; 822:330–333.
35) D. Blessborn, S. Römsing, A. Annerberg, D. Sundquist, et al., Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper. Journal of Pharmaceutical and Biomedical Analysis. 2007; 45:282–287.
36) F. Khuda, Z. Iqbal , Y. Shah , L. Ahmmad, et al., Method development and validation for simultaneous determination of lumefantrine and its major metabolite, desbutyl lumefantrine inhuman plasma using RP-HPLC/UV detection. Journal of Chromatography B. 2014; 944:114-122.
37) N. Lindegardh, A Annerberg, D Blessborn, Y Bergqvist, et.al., Development and validation of a bioanalytical method using automated solid-phase extraction and LC-UV for the simultaneous determination of lumefantrine and its desbutyl metabolite in plasma. J. Pharm. Biomed. Anal. 2005; 37:1081–1088.
38) M. Ntale, J. Ogwal-Okeng, M. Mahindi, L. Gustafsson, et.al., A field-adapted sampling and HPLC quantification method for lumefantrine and its desbutyl metabolite in whole blood spotted on filter paper. Journal of Chromatography B. 2008; 876:261–265
39) Sarah Aparecida Siqueira, Christion Fernandes, Isabela Costa César, Chiral Method by Normal Phase HPLC–UV for Quantitation of Lumefantrine Enantiomers in Tablet Formulations. Chromatographia.
40) P. Hamrapurkar, M. Phale, S. Pawar, P. Patil, et.al.,A simple and precise method for quantitative analysis of lumefantrine by planar chromatography. Pharmaceutical Methods. 2010;2(1):44-48.
41) M. Verbeken, S. Suleman, B. Baert, E. Vangheluwe, et al., Stability-indicating HPLC-DAD / UV-ESI/MS impurity profiling of the anti-malarial drug lumefantrine. Malaria Journal. 2011; 10:51:1-9.
42) Wahajuddin, Singh SP , Jain G.k, Determination of lumefantrine in rat plasma by liquid-liquid extraction using LC–MS/MS with electrospray ionization: assay development, validation and application to a pharmacokinetic study. J. Chromatogr. B. 2009;877:1133-1139.
43) L. Huang, X. Li, F. Marzan, P. Lizak, et al., Determination of lumefantrine in small-volume human plasma by LC–MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation. Bioanalysis. 2012;4(2):157-166.
44) K. Govender, L. Gibhard, L. Du Plessis, L. Wiesner, Development and validation of a LC–MS/MS method for thequantitation of lumefantrine in mouse whole blood and plasma. Journal of Chromatography B. 2015;985:6–13.
45) Prerana Sethi, Virendra K. Dua, Rajeev Jain, A LC-MS/MS Method For The Determinationof Lumefantrine And Its Metabolite Desbutyl-Lumefantrine In Plasma From Patients Infected With Plasmodium Falciparum Malaria. Journal of Liquid Chromatography & Related Technologies. 2011;34:2674-2688.
46) A. Silva, N. Mwebaza,M. Ntale, L. Gustafsson, et al., A fast and sensitive method for quantifying lumefantrine and desbutyl-lumefantrine using LC–MS/MS. Journal of Chromatography B. 2015;1004:60–66.
47) Karajgi S.R, Tanveer A.R , Kalyane N.Y,Simultaneous Determination of Artemether and Lumefantrine by Area Under Curve UV Spectrophotometric Method. J. Pharm. Sci. & Res. Vol. 2016; 8(6):506-511.
48) Karen Gaudin, Tina Kauss, Alexandra Gaubert, Vincent Viaud, et al., Simultaneous Determination of Artemether and Azithromycin in Suppositories by Reversed Phase HPLC. Analytical Letters.2011; 44:2732–2743.
49) R. Kalra, A. Diwan, J. Kumar, S. Sharma, Simultaneous Estimation Of Artemether & Curcumin By RP-HPLC Method. Pharmacophore. 2016;7(3):141-151.
50) Kenneth Maduabuchi Ezealisiji, Ifeyinwa Chijioke-Nwauche, Igbinaduwa Patrick, Chijioke Adonye Nwauche, Bioavailability And Bioequivalence Evaluation Of Lokmal® (Artemether-Lumefantrine 80/480 Mg Fixed Dose Tablet): An Emzor® Pharmaceutical Product. Ejpmr.2018;5(10:nrique Andrade Nogueira, Gerson Antonio Pianetti, Simultaneous determination of artemether and lumefantrine in fixed dose combination tablets by HPLC with UV detection. Journal of Pharmaceutical and Biomedical Analysis. 2008;48:951-954.
51) Prasenjit Mondal, Novel Stability Indicating Validated RP-HPLC Method for Simultaneous Quantification of Artemether and Lumefantrine in Bulk and Tablet. Current Pharmaceutical Analysis. 2014;10(4):1-8.
52) Sai Sandeep Mannemala, Janaki Sankarachari Krishnan Nagarajan, Development and validation of a generic liquid chromatographic method for the simultaneous determination of five commonly used antimalarial drugs: Application to pharmaceutical formulations and human plasma. J. Sep. Sci. 2015;38:1521-1528.
53) T.M. Kalyankar, R. B. Kakade, Reversed-Phase Liquid Chromatographic Method for Simultaneous Determination of Artemether and Lumefantrine in Pharmaceutical Preparation. International Journal of ChemTech Research. 2011;3(3):1722-1727.
54) Mannur Vinodh, Mastiholimath Vinayak, Patware Pankaj, Kharya Rahul, et al., Analytical Method Development And Validation For Simultaneous Estimation Of Artemether And Lumefantrine In Pure And Pharmaceutical Dosage Form Using RP-HPLC Method. Malaysian Journal of Analytical Sciences. 2013;17(3):348-358.
55) S. Suleman, K. Vandercruyssen, E. Wynendaele,M. D’Hondt, et al., A rapid stability-indicating, fused-core HPLC method for simultaneous determination of β-artemether and lumefantrine in anti-malarial fixed dose combination products. Malaria Journal. 2013;12(145):1-11
56) Sukanya Bandari, Mohan Gaud, P. Anitha, Stability indicating Ultra Performance Liquid Chromatography method development and validation for simultaneous estimation of artemether and lumefantrine in bulk and pharmaceutical dosage form. Journal of Drug Delivery & Therapeutics. 2019;9(2):217-221.
57) P. Saini, R Singh, S Mathur, G Singh, et. al., A Simple and Sensitive HPTLC Method for Quantitative Analysis of Artemether and Lumefantrine in Tablets. Journal of Planar Chromatography. 2010; 23(2):119-122.
58) S. Meena, S. M. Sandhya, Analysis Of Active Ingredients, Lumefantrine And Artemether In Combined Anti-Malarial Tablet By HPTLC With Densitometric Measurement Before And After Derivatisation. Journal of Liquid Chromatography & Related Technologies, 2014; 37(10):1416-1426.
59) .I. Costa Cesar, J. Ribeiro, L. Teixeira, K. Bellorio, Liquid chromatography–tandem mass spectrometry for the simultaneous quantitation of artemether and lumefantrine in human plasma: Application for a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis. 2011;54:114-120.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Innovative Science & Technology affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJIST.
Download link for COPYRIGHT FORM